{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:02:15Z","timestamp":1787022135006,"version":"build-2736575974"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Ropivacaine oil delivery depot (RODD) can slowly release ropivacaine and block nerves for a long timejavascript:;. The aim of the present work was to investigate the safety, pharmacokinetics, and preliminary pharmacodynamics of RODD in subcutaneous injection among healthy subjects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The abdomens of 3 subjects were subcutaneously administered with a single-needle RODD containing 12~30 mg of ropivacaine. The irritation, nerve blocking range and optimum dose were investigated. Forty-one subjects were divided into RODD groups containing 150, 230, 300, 350 and 400 mg of ropivacaine and a ropivacaine hydrochloride injection (RHI) 150 mg group. Multineedle subcutaneous injection of RODD or RHI was performed in the abdomens of the subjects. The primary endpoint was a safe dose or a maximum dose of ropivacaine (400 mg). Subjects\u2019 vital signs were observed; their blood was analyzed; their cardiovascular system and nervous systems were monitored, and their dermatological reactions were observed and scored. Second, the ropivacaine concentrations in plasma were determined, pharmacokinetic parameters were calculated, and the anesthetic effects of RODD were studied, including RODD onset time, duration and intensity of nerve block.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Single-needle injection of RODD 24 mg was optimal for 3 subjects, and the range of nerve block was 42.5\u00b120.8 mm. Multineedle subcutaneous injection of RODD in the abdomens of subjects was safe, and all adverse events were no more severe than grade II. The incidence rate of grade II adverse events, such as pain, and abnormal ST and ST-T segment changes on electrocardiography, was approximately 1%. The incidence rate of grade I adverse events, including erythema, papules, hypertriglyceridemia, and hypotension was greater than 10%. Erythema and papules were relieved after 24 h and disappeared after 72 h. Other adverse reactions disappeared after 7 days. The curve of ropivacaine concentration-time in plasma presented a bimodal profile. The results showed that ropivacaine was slowly released from the RODD. Compared with the 150 mg RHI group, T\n                      <jats:sub>max<\/jats:sub>\n                      was longer in the RODD groups. In particular, T\n                      <jats:sub>max<\/jats:sub>\n                      in the 400 mg RODD group was longer than that in the RHI group (11.8\u00b14.6 h vs. 0.77\u00b10.06 h). The C\n                      <jats:sub>max<\/jats:sub>\n                      in the 150 mg RODD group was lower than that in the 150 mg RHI group (0.35\u00b10.09 vs. 0.58\u00b10.13 \u03bcg\u00b7mL\n                      <jats:sup>-1<\/jats:sup>\n                      ). In particular, the C\n                      <jats:sub>max<\/jats:sub>\n                      increased by 48% when the dose was increased by 2.6 times in the 400 mg group. C\n                      <jats:sub>max<\/jats:sub>\n                      , the AUC value and the intensity of the nerve block increased with increasing doses of RODD. Among them, the 400 mg RODD group presented the strongest nerve block (the percentage of level 2 and 3, 42.9%). The corresponding median onset time was 0.42 h, and the duration median was 35.7\u205347.7 h.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      RODD has a sustained release effect. Compared with the RHI group, T\n                      <jats:sub>max<\/jats:sub>\n                      was delayed in the RODD groups, and the duration of nerve block was long. No abnormal reaction was found in the RODD group containing 400 mg of ropivacaine after subcutaneous injection among healthy subjects, suggesting that RODD was adequately safe.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec005\">\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/Chictr.org\" xlink:type=\"simple\">Chictr.org<\/jats:ext-link>\n                      :\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.chictr.org.cn\/CTR2200058122\" xlink:type=\"simple\">CTR2200058122<\/jats:ext-link>\n                      ;\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/Chinadrugtrials.org\" xlink:type=\"simple\">Chinadrugtrials.org<\/jats:ext-link>\n                      :\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/Chinadrugtrials.org\/CTR20192280\" xlink:type=\"simple\">CTR20192280<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0291793","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T13:26:59Z","timestamp":1695130019000},"page":"e0291793","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["A randomized trial: The safety, pharmacokinetics and preliminary pharmacodynamics of ropivacaine oil delivery depot in healthy subjects"],"prefix":"10.1371","volume":"18","author":[{"given":"Wu-dang","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-ling","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-xia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-qi","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-ping","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-quan","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3451-3747","authenticated-orcid":true,"given":"Yong-xiao","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,9,19]]},"reference":[{"issue":"5","key":"pone.0291793.ref001","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2165\/00003495-200060050-00007","article-title":"Ropivacaine: an update of its use in regional anaesthesia","volume":"60","author":"KJ McClellan","year":"2000","journal-title":"Drugs"},{"issue":"5","key":"pone.0291793.ref002","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/bja\/78.5.507","article-title":"Central nervous and cardiovascular effects of i.v. infusions of ropivacaine, bupivacaine and placebo in volunteers","volume":"78","author":"K Knudsen","year":"1997","journal-title":"Br J Anaesth"},{"issue":"4","key":"pone.0291793.ref003","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2199\/jjsca.29.519","article-title":"Ropivacaine: pharmacokinetics and toxicity.","volume":"29","author":"ODA Yutaka","year":"2009","journal-title":"The journal of Japan Society for Clinical Anesthesia"},{"issue":"8","key":"pone.0291793.ref004","first-page":"472","article-title":"Analysis of bupivacaine and ropivacaine-related cardiac arrests in regional anesthesia: a systematic review of case reports.","volume":"68","author":"D Viderman","year":"2021","journal-title":"Rev Esp Anestesiol Reanim (Engl Ed)."},{"issue":"1","key":"pone.0291793.ref005","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1186\/s40064-016-2856-3","article-title":"Effect of skin infiltration with ropivacaine on postoperative pain in patients undergoing craniotomy","volume":"5","author":"HY Zhou","year":"2016","journal-title":"Springerplus"},{"issue":"4","key":"pone.0291793.ref006","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4174\/astr.2015.88.4.193","article-title":"The benefits of preincision ropivacaine infiltration for reducing postoperative pain after robotic bilateral axillo-breast approach thyroidectomy: a prospective, randomized, double-blind, placebo-controlled study","volume":"88","author":"KH Kang","year":"2015","journal-title":"Ann Surg Treat Res"},{"issue":"6","key":"pone.0291793.ref007","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/AJP.0000000000000928","article-title":"The effect of epidural nalbuphine combined with ropivacaine on epidural analgesia during labor: a multicenter, randomized, double-blind, controlled study","volume":"37","author":"XF Sun","year":"2021","journal-title":"Clin J Pain"},{"issue":"05","key":"pone.0291793.ref008","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/CM9.0000000000000669","article-title":"Optimum interval time of programmed intermittent epidural bolus of ropivacaine 0.08 with sufentanyl 0.3 \u03bcg\/mL for labor analgesia: a biased-coin up-and-down sequential allocation trial","volume":"133","author":"SQ Zhou","year":"2020","journal-title":"Chin Med J (Engl)."},{"issue":"3","key":"pone.0291793.ref009","doi-asserted-by":"crossref","first-page":"14","DOI":"10.33545\/26643766.2020.v3.i3a.140","article-title":"A comparative study of epidural ropivacaine 0.2% with nalbuphine and ropivacaine 0.2% with fentanyl in unilateral total knee replacement surgeries","volume":"3","author":"PD Shelke","year":"2020","journal-title":"Int J Med Anesthesiology"},{"issue":"7","key":"pone.0291793.ref010","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/pan.12919","article-title":"The effect of continuous wound infusion of ropivacaine on postoperative pain after median sternotomy and mediastinal drain in children","volume":"26","author":"I Mattila","year":"2016","journal-title":"Paediatr Anaesth"},{"issue":"8","key":"pone.0291793.ref011","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jclinane.2015.03.006","article-title":"The effect of continuous interscalene brachial plexus block with 0.125% bupivacaine vs 0.2% ropivacaine on pain relief, diaphragmatic motility, and ventilatory function","volume":"27","author":"DW Choromanski","year":"2015","journal-title":"J Clin Anesth"},{"key":"pone.0291793.ref012","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2147\/JPR.S247158","article-title":"Comparison of effectiveness of ropivacaine infusion regimens for continuous femoral nerve block for recovery after total knee arthroplasty: a randomized double-blind trial","volume":"13","author":"Y Zhang","year":"2020","journal-title":"J Pain Res"},{"key":"pone.0291793.ref013","first-page":"8542849","article-title":"Local infiltration analgesia with ropivacaine improves postoperative pain control in ankle fracture patients: a retrospective cohort study","volume":"2020","author":"BL Li","year":"2020","journal-title":"Pain Research and Management"},{"issue":"1","key":"pone.0291793.ref014","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jmig.2015.07.018","article-title":"Surgical pain control with ropivacaine by atomized delivery (spray): a randomized controlled trial","volume":"23","author":"GG Collins","year":"2016","journal-title":"J Minim Invasive Gynecol"},{"key":"pone.0291793.ref015","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.urology.2017.12.004","article-title":"Effect of intercostal nerve block and nephrostomy tract infiltration with ropivacaine on postoperative pain control after tubeless percutaneous nephrolithotomy: a prospective, randomized, and case-controlled trial","volume":"114","author":"SW Choi","year":"2018","journal-title":"Urology"},{"issue":"1","key":"pone.0291793.ref016","doi-asserted-by":"crossref","first-page":"115","DOI":"10.18203\/2349-2902.isj20175550","article-title":"Multisite ropivacaine for pain relief after laparoscopic cholecystectomy: a placebo controlled study at a tertiary care teaching hospital","volume":"5","author":"D Samal","year":"2018","journal-title":"Int Surg J"},{"issue":"9","key":"pone.0291793.ref017","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1097\/EJA.0000000000001206","article-title":"Efficacy of incisional infiltration and intraperitoneal instillation of ropivacaine for the management of pain after laparoscopic sleeve gastrectomy: A randomised clinical trial","volume":"37","author":"L Alevizos","year":"2020","journal-title":"Eur J Anaesthesiol"},{"issue":"12","key":"pone.0291793.ref018","first-page":"22460","article-title":"Combined usage with intraperitoneal and incisional ropivacaine reduces pain severity after laparoscopic cholecystectomy","volume":"8","author":"DS Liu","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"pone.0291793.ref019","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.phrs.2017.02.012","article-title":"Postoperative hyperalgesia-A clinically applicable narrative review","volume":"120","author":"AA Weinbroum","year":"2017","journal-title":"Pharmacol Res"},{"issue":"4","key":"pone.0291793.ref020","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1017\/S0265021507003031","article-title":"The prevalence of postoperative pain in a sample of 1490 surgical inpatients.","volume":"25","author":"M Sommer","year":"2008","journal-title":"Eur J Anaesthesiol"},{"issue":"2","key":"pone.0291793.ref021","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s11419-021-00574-x","article-title":"Two fatal and four surviving cases after accidental infusion of ropivacaine.","volume":"39","author":"M Winkler","year":"2021","journal-title":"Forensic Toxicol"},{"key":"pone.0291793.ref022","doi-asserted-by":"crossref","first-page":"121315","DOI":"10.1016\/j.ijpharm.2021.121315","article-title":"Near-infrared triggered ropivacaine liposomal gel for adjustable and prolonged local anaesthesia","volume":"611","author":"Y Hou","year":"2022","journal-title":"Int J Pharm"},{"issue":"4","key":"pone.0291793.ref023","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.athoracsur.2021.08.077","article-title":"Randomized trial of poloxamer 407-based ropivacaine hydrogel after thoracoscopic pulmonary resection.","volume":"114","author":"JH Jeon","year":"2022","journal-title":"Ann Thorac Surg"},{"issue":"11","key":"pone.0291793.ref024","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.7150\/thno.74845","article-title":"Injectable electrospun fiber-hydrogel composite sequentially releasing clonidine and ropivacaine for prolonged and walking regional analgesia","volume":"12","author":"S Chen","year":"2022","journal-title":"Theranostics"},{"issue":"1","key":"pone.0291793.ref025","doi-asserted-by":"crossref","first-page":"e0117321","DOI":"10.1371\/journal.pone.0117321","article-title":"Epidural sustained release ropivacaine prolongs anti-allodynia and anti-hyperalgesia in developing and established neuropathic pain","volume":"10","author":"TF Li","year":"2015","journal-title":"PlOS ONE"},{"issue":"1","key":"pone.0291793.ref026","first-page":"37","article-title":"Pharmacokinetics and toxicity of oily delivery system of ropivacaine via subcutaneous injection in beagle dogs","volume":"13","author":"MQ Hui","year":"2018","journal-title":"Journal of Pharmacology and Toxicology"},{"issue":"4","key":"pone.0291793.ref027","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ajem.2018.01.008","article-title":"A systematic review of the pain scales in adults: Which to use?","volume":"36","author":"O Karcioglu","year":"2018","journal-title":"Am J Emerg Med"},{"issue":"5","key":"pone.0291793.ref028","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1515\/cclm-2018-1298","article-title":"Validation according to european and american regulatory agencies guidelines of an LC-MS\/MS method for the quantification of free and total ropivacaine in human plasma","volume":"58","author":"E Lamy","year":"2020","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"pone.0291793.ref029","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jchromb.2009.11.028","article-title":"Column-switching HPLC-MS\/MS analysis of ropivacaine in serum, ultrafiltrate and drainage blood for validating the safety of blood reinfusion","volume":"878","author":"T Breindahl","year":"2010","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"4","key":"pone.0291793.ref030","first-page":"736","article-title":"Determination of ropivacaine in rat plasma with liquid chromatography-tandem mass spectrometry2016","volume":"43","author":"JZ Zhou","journal-title":"Journal of International Pharmaceutical Research"},{"issue":"5","key":"pone.0291793.ref031","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1586\/14737175.4.5.781","article-title":"Ropivacaine: a pharmacological review","volume":"4","author":"TG Hansen","year":"2004","journal-title":"Expert Rev Neurother"},{"issue":"8","key":"pone.0291793.ref032","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1034\/j.1398-9995.2003.00221.x","article-title":"Side effects to castor oil.","volume":"58","author":"L Di Berardino","year":"2003","journal-title":"Allergy"},{"key":"pone.0291793.ref033","first-page":"31","article-title":"Final report on the safety assessment of ricinus communis (castor) seed oil, hydrogenated castor oil, glyceryl ricinoleate, glyceryl ricinoleate se, ricinoleic acid, potassium ricinoleate, sodium ricinoleate, zinc ricinoleate, cetyl ricinoleate, ethyl ricinoleate, glycol ricinoleate, isopropyl ricinoleate, methyl ricinoleate, and octyldodecyl ricinoleate","volume":"3","year":"2007","journal-title":"Int J Toxicol"},{"issue":"1","key":"pone.0291793.ref034","doi-asserted-by":"crossref","first-page":"e000262","DOI":"10.1136\/vetreco-2017-000262","article-title":"Comparison of pain response after subcutaneous injection of two maropitant formulations to beagle dogs","volume":"5","author":"N Deckers","year":"2018","journal-title":"Veterinary Record Open"},{"issue":"6","key":"pone.0291793.ref035","doi-asserted-by":"crossref","first-page":"e13103","DOI":"10.1111\/dth.13103","article-title":"Treatment of demodex-associated inflammatory skin conditions: a systematic review.","volume":"32","author":"S Jacob","year":"2019","journal-title":"Dermatol Ther"},{"issue":"6","key":"pone.0291793.ref036","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3390\/nu10060658","article-title":"Olive oil and soybean oil based intravenous lipid emulsions, liver biochemistry and clinical outcomes","volume":"10","author":"F Araujo","year":"2018","journal-title":"Nutrients"},{"issue":"6","key":"pone.0291793.ref037","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1017\/S0265021505000773","article-title":"Sciatic nerve block with 0.5% levobupivacaine, 0.75% levobupivacaine or 0.75% ropivacaine: a double-blind, randomized comparison","volume":"22","author":"A Casati","year":"2005","journal-title":"Eur J Anaesthesiol"},{"issue":"2","key":"pone.0291793.ref038","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4103\/0019-5049.79875","article-title":"Ropivacaine: a review of its pharmacology and clinical use","volume":"55","author":"G Kuthiala","year":"2017","journal-title":"Indian J Anaesth"},{"issue":"1","key":"pone.0291793.ref039","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00000539-200001000-00028","article-title":"Three-in-one blocks with ropivacaine: evaluation of sensory onset time and quality of sensory block.","volume":"90","author":"P Marhofer","year":"2000","journal-title":"Anesth Analg"},{"issue":"1","key":"pone.0291793.ref040","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12871-022-01653-1","article-title":"Pharmacodynamics, toxicology and toxicokinetics of ropivacaine oil delivery depot","volume":"22","author":"WD Lu","year":"2022","journal-title":"BMC Anesthesiol"},{"issue":"6","key":"pone.0291793.ref041","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/bja\/aet015","article-title":"Symptomatic local anaesthetic toxicity and plasma ropivacaine concentrations after transversus abdominis plane block for Caesarean section","volume":"110","author":"JD Griffiths","year":"2013","journal-title":"Br J Anaesth"},{"issue":"1\u20132","key":"pone.0291793.ref042","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ijpharm.2017.06.055","article-title":"The contribution of the in-vivo fate of an oil depot to drug absorption","volume":"528","author":"RW Kalicharan","year":"2017","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"pone.0291793.ref043","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijpharm.2016.03.064","article-title":"Spatial distribution of oil depots monitored in human muscle using MRI","volume":"505","author":"RW Kalicharan","year":"2016","journal-title":"Int J Pharm"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0291793","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T13:27:39Z","timestamp":1695130059000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0291793"}},"subtitle":[],"editor":[{"given":"Jos\u00e9 Luiz Fernandes","family":"Vieira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,9,19]]},"references-count":43,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0291793","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,19]]}}}